Today: 29 April 2026
Carvana stock slips, but Morgan Stanley lifts bull case to $750 — what traders watch next
9 January 2026
1 min read

Carvana stock slips, but Morgan Stanley lifts bull case to $750 — what traders watch next

New York, January 8, 2026, 21:30 (EST) — Market closed

  • • Morgan Stanley kept an Overweight on Carvana and lifted its bull-case scenario to $750
  • • CVNA ended down 1.8%, with traders watching the week’s macro data for the next swing
  • • Next up: Friday’s U.S. jobs report, then consumer sentiment; earnings timing still not confirmed

Morgan Stanley analyst Andrew Percoco maintained an Overweight rating and a $450 price target on Carvana (CVNA) and raised his bull-case scenario to $750, TheFly reported Thursday, citing the company’s dealership purchases as a sign it is “readily expanding” beyond used cars. Shares of Carvana fell 1.8% to $442.58 after trading between $433.30 and $457.22; the stock is up about 11% so far in 2026 but about 9% below its 52-week high of $485.33.

The call matters because it shifts the Carvana story away from a pure wager on the used-car cycle. Percoco’s “Bull case” is the optimistic scenario, and it hinges on Carvana widening its total addressable market, or TAM — the pool of customers it can sell to — by moving into franchised dealerships.

Macro data could still have more sway than any one analyst note. The U.S. Labor Department releases the December employment report at 8:30 a.m. ET on Friday, followed by the University of Michigan’s preliminary January consumer sentiment reading at 10 a.m. ET.

Used-vehicle pricing remains another live wire for the group. Carfax data cited by Investopedia showed used hybrids and electric vehicles logged the sharpest price drops in December, a shift that could flow through to retailers’ gross profit per unit — what they make on each car sold — if pricing resets faster than costs.

Carvana moved against some peers on Thursday. CarMax (KMX) rose 3.5% for a fifth straight gain, even as U.S. indexes ended mixed; the S&P 500 was essentially flat while the Nasdaq fell about 0.4%.

Rates slipped back into focus. Fed Governor Stephen Miran said on Thursday he supports 150 basis points of rate cuts this year, a view that could reshape how investors price consumer credit and funding costs into 2026.

Carvana’s shareholder base has shifted after a volatile stretch. S&P Dow Jones Indices said last month Carvana would join the S&P 500 in a quarterly rebalance, effective before trading on Dec. 22.

But the stock can still turn fast. A further slide in used-car prices, tighter credit, or a risk-off turn in markets would pressure a name that has already seen wide daily swings; traders will watch the $433 area as near-term support.

Beyond Friday’s data, the next company marker is earnings: Nasdaq data show Carvana is estimated to report on Feb. 18, though the company has not confirmed a date. The Fed’s next policy meeting is scheduled for Jan. 27-28, another test for rate-sensitive consumer names, while attention first shifts to Friday’s payrolls report at 8:30 a.m. ET.

Stock Market Today

  • ASX Growth Companies with High Insider Ownership to Watch in April 2026
    April 29, 2026, 4:14 PM EDT. As the Australian share market dips for the seventh day amid inflation and rate hike concerns, growth companies with high insider ownership stand out. Insider ownership signals strong confidence from company insiders. Top performers include Torque Metals (ASX:TOR) with 18.3% insider ownership and 94.2% earnings growth, Magnetic Resources (ASX:MAU) with 33.6% ownership and 124.2% growth, and Forrestania Resources (ASX:FRS) at 32.4% ownership and 102.3% growth. Medical AI firm Artrya (ASX:AYA) shows a 61.9% revenue growth forecast and 13.5% insider stake, despite recent losses, projecting profitability within three years. IperionX (ASX:IPX) highlights potential with 17.2% insider ownership and expected 61.6% annual revenue growth. These stocks offer investors exposure to companies where insiders have skin in the game amid bearish market sentiment.

Latest article

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

Vita Coco Stock Surges After COCO Earnings Beat and Coconut Water Demand Lifts 2026 Outlook

29 April 2026
Vita Coco shares jumped 27% Wednesday after first-quarter net sales rose 37% to $180 million, beating analyst expectations. The company raised its 2026 revenue outlook to $720–$735 million and lifted adjusted EBITDA guidance. Diluted earnings reached $0.50 per share, up from $0.31 a year earlier. Gross margin improved to 39.9% despite higher logistics and tariff costs.
Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

Marathon Petroleum Stock Jumps Before Earnings as Refining Margins Put Wall Street on Alert

29 April 2026
Marathon Petroleum shares rose 3.2% to $240.05 Wednesday as investors anticipated its May 5 earnings report, following a surge in fuel margins during the first quarter. Phillips 66 and Valero also gained after posting stronger-than-expected results. Marathon’s Robinson refinery in Illinois began planned maintenance in March. U.S. gasoline prices hit $4.18 a gallon, the highest since 2022, according to AAA.
Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

Why MaxLinear Stock Is Surging as AI Data-Center Demand Rewrites the Story

29 April 2026
MaxLinear shares rose about 34% to $69.58 on Wednesday after Loop Capital upgraded the stock and raised its target to $75. The surge followed a first-quarter report showing infrastructure revenue up 136% to become the company’s largest segment. Total revenue climbed 43% to $137.2 million. MaxLinear guided second-quarter revenue to $160–$170 million, citing strong demand for data-center optical products.
Nebius stock (NBIS) ends higher as Nvidia Rubin rollout news sinks in
Previous Story

Nebius stock (NBIS) ends higher as Nvidia Rubin rollout news sinks in

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
Next Story

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

Go toTop